On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.

FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.

On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.

Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.

Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.

Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.

April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.

BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.

Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.

April 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.